Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Main effects and interactions of cerebral hemispheres, gender, and age in the calculation of volumes and asymmetries of selected structures of episodic memory.

Ramirez-Carmona R, Garcia-Lazaro HG, Dominguez-Corrales B, Aguilar-Castañeda E, Roldan-Valadez E.

Funct Neurol. 2016 Oct/Dec;31(4):257-264.

2.

Multimodal characterization of older APOE2 carriers reveals selective reduction of amyloid load.

Grothe MJ, Villeneuve S, Dyrba M, Bartrés-Faz D, Wirth M; Alzheimer's Disease Neuroimaging Initiative..

Neurology. 2017 Feb 7;88(6):569-576. doi: 10.1212/WNL.0000000000003585. Epub 2017 Jan 6.

PMID:
28062720
3.

Apolipoprotein E and Sex Bias in Cerebrovascular Aging of Men and Mice.

Finch CE, Shams S.

Trends Neurosci. 2016 Sep;39(9):625-37. doi: 10.1016/j.tins.2016.07.002. Epub 2016 Aug 18. Review.

PMID:
27546867
4.

Active Cigarette Smoking in Cognitively-Normal Elders and Probable Alzheimer's Disease is Associated with Elevated Cerebrospinal Fluid Oxidative Stress Biomarkers.

Durazzo TC, Korecka M, Trojanowski JQ, Weiner MW, O' Hara R, Ashford JW, Shaw LM; Alzheimer’s Disease Neuroimaging Initiative..

J Alzheimers Dis. 2016 Jul 25;54(1):99-107. doi: 10.3233/JAD-160413.

PMID:
27472882
5.

APOE2 Is Associated with Spatial Navigational Strategies and Increased Gray Matter in the Hippocampus.

Konishi K, Bhat V, Banner H, Poirier J, Joober R, Bohbot VD.

Front Hum Neurosci. 2016 Jul 13;10:349. doi: 10.3389/fnhum.2016.00349. eCollection 2016 Jul 13.

6.

The effects of sequential treatments on hippocampal volumes in malignant glioma patients.

Nolen SC, Lee B, Shantharam S, Yu HJ, Su L, Billimek J, Bota DA.

J Neurooncol. 2016 Sep;129(3):433-41. doi: 10.1007/s11060-016-2188-8. Epub 2016 Jul 8.

PMID:
27393350
7.

Genes associated with Alzheimer's disease: an overview and current status.

Giri M, Zhang M, Lü Y.

Clin Interv Aging. 2016 May 17;11:665-81. doi: 10.2147/CIA.S105769. eCollection 2016 May 17. Review.

8.

ApoE2 and Alzheimer's disease: time to take a closer look.

Wu L, Zhao L.

Neural Regen Res. 2016 Mar;11(3):412-3. doi: 10.4103/1673-5374.179044. No abstract available.

9.

Three dimensions of the amyloid hypothesis: time, space and 'wingmen'.

Musiek ES, Holtzman DM.

Nat Neurosci. 2015 Jun;18(6):800-6. doi: 10.1038/nn.4018. Review.

10.

History of cigarette smoking in cognitively-normal elders is associated with elevated cerebrospinal fluid biomarkers of oxidative stress.

Durazzo TC, Mattsson N, Weiner MW, Korecka M, Trojanowski JQ, Shaw LM; Alzheimer's Disease Neuroimaging Initiative..

Drug Alcohol Depend. 2014 Sep 1;142:262-8. doi: 10.1016/j.drugalcdep.2014.06.030. Epub 2014 Jul 3.

11.

APOE ε4 is associated with disproportionate progressive hippocampal atrophy in AD.

Manning EN, Barnes J, Cash DM, Bartlett JW, Leung KK, Ourselin S, Fox NC; Alzheimer's Disease NeuroImaging Initiative..

PLoS One. 2014 May 30;9(5):e97608. doi: 10.1371/journal.pone.0097608. eCollection 2014 May 30. Erratum in: PLoS One. 2014;9(7):e104482.

12.

Mapping the effect of the apolipoprotein E genotype on 4-year atrophy rates in an Alzheimer disease-related brain network.

Hostage CA, Choudhury KR, Murali Doraiswamy P, Petrella JR; Alzheimer's Disease Neuroimaging Initiative..

Radiology. 2014 Apr;271(1):211-9. doi: 10.1148/radiol.13131041. Epub 2013 Dec 12.

13.

Alzheimer's disease susceptibility genes APOE and TOMM40, and hippocampal volumes in the Lothian birth cohort 1936.

Lyall DM, Royle NA, Harris SE, Bastin ME, Maniega SM, Murray C, Lutz MW, Saunders AM, Roses AD, del Valdés Hernández MC, Starr JM, Porteous DJ, Wardlaw JM, Deary IJ.

PLoS One. 2013 Nov 15;8(11):e80513. doi: 10.1371/journal.pone.0080513. eCollection 2013 Nov 15.

14.

The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.

Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR, Jagust W, Liu E, Morris JC, Petersen RC, Saykin AJ, Schmidt ME, Shaw L, Shen L, Siuciak JA, Soares H, Toga AW, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative..

Alzheimers Dement. 2013 Sep;9(5):e111-94. doi: 10.1016/j.jalz.2013.05.1769. Epub 2013 Aug 7. Review.

15.

Cerebrospinal fluid biomarkers of Alzheimer's disease in healthy elderly.

Randall C, Mosconi L, de Leon M, Glodzik L.

Front Biosci (Landmark Ed). 2013 Jun 1;18:1150-73. Review.

16.

Dissecting the gene dose-effects of the APOE ε4 and ε2 alleles on hippocampal volumes in aging and Alzheimer's disease.

Hostage CA, Roy Choudhury K, Doraiswamy PM, Petrella JR; Alzheimer’s Disease Neuroimaging Initiative..

PLoS One. 2013;8(2):e54483. doi: 10.1371/journal.pone.0054483. Epub 2013 Feb 6.

17.

Total ApoE and ApoE4 isoform assays in an Alzheimer's disease case-control study by targeted mass spectrometry (n=669): a pilot assay for methionine-containing proteotypic peptides.

Simon R, Girod M, Fonbonne C, Salvador A, Clément Y, Lantéri P, Amouyel P, Lambert JC, Lemoine J.

Mol Cell Proteomics. 2012 Nov;11(11):1389-403. doi: 10.1074/mcp.M112.018861. Epub 2012 Aug 23.

18.

Characterizing the preclinical stages of Alzheimer's disease and the prospect of presymptomatic intervention.

Caselli RJ, Reiman EM.

J Alzheimers Dis. 2013;33 Suppl 1:S405-16. doi: 10.3233/JAD-2012-129026. Review.

19.

Within-subject template estimation for unbiased longitudinal image analysis.

Reuter M, Schmansky NJ, Rosas HD, Fischl B.

Neuroimage. 2012 Jul 16;61(4):1402-18. doi: 10.1016/j.neuroimage.2012.02.084. Epub 2012 Mar 10.

20.

White matter alterations in cognitively normal apoE ε2 carriers: insight into Alzheimer resistance?

Chiang GC, Zhan W, Schuff N, Weiner MW.

AJNR Am J Neuroradiol. 2012 Aug;33(7):1392-7. doi: 10.3174/ajnr.A2984. Epub 2012 Mar 1.

Supplemental Content

Support Center